| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial.
|
Lancet
|
2009
|
5.30
|
|
2
|
A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis.
|
Int J Tuberc Lung Dis
|
2008
|
3.77
|
|
3
|
Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects.
|
Antimicrob Agents Chemother
|
1998
|
3.60
|
|
4
|
Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials.
|
Clin Pharmacokinet
|
2001
|
2.68
|
|
5
|
Sputum monitoring during tuberculosis treatment for predicting outcome: systematic review and meta-analysis.
|
Lancet Infect Dis
|
2010
|
2.61
|
|
6
|
Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy.
|
Am J Respir Crit Care Med
|
2004
|
2.40
|
|
7
|
Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man.
|
J Antimicrob Chemother
|
1999
|
2.37
|
|
8
|
Pharmacokinetics of a once-daily oral dose of moxifloxacin (Bay 12-8039), a new enantiomerically pure 8-methoxy quinolone.
|
Antimicrob Agents Chemother
|
1999
|
1.88
|
|
9
|
Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial.
|
Am J Respir Crit Care Med
|
2015
|
1.86
|
|
10
|
Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium.
|
J Infect Dis
|
2012
|
1.53
|
|
11
|
Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis.
|
Clin Infect Dis
|
2007
|
1.30
|
|
12
|
Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin.
|
Antimicrob Agents Chemother
|
2007
|
1.26
|
|
13
|
Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy.
|
J Antimicrob Chemother
|
1999
|
1.24
|
|
14
|
Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers.
|
Clin Pharmacol Ther
|
2012
|
1.23
|
|
15
|
Rifapentine and isoniazid in the continuation phase of treating pulmonary tuberculosis. Initial report.
|
Am J Respir Crit Care Med
|
1998
|
1.20
|
|
16
|
Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations.
|
Antimicrob Agents Chemother
|
2008
|
1.14
|
|
17
|
Pharmacokinetics, safety and tolerability of moxifloxacin, a novel 8-methoxyfluoroquinolone, after repeated oral administration.
|
Clin Pharmacokinet
|
2001
|
1.03
|
|
18
|
Absolute bioavailability of moxifloxacin.
|
Clin Ther
|
1999
|
0.96
|
|
19
|
Effect of food on the pharmacokinetics of a single oral dose of moxifloxacin 400mg in healthy male volunteers.
|
Clin Pharmacokinet
|
2001
|
0.88
|
|
20
|
Effects of dairy products on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in healthy volunteers.
|
Clin Pharmacokinet
|
2001
|
0.87
|
|
21
|
Population pharmacokinetics of rifapentine and desacetyl rifapentine in healthy volunteers: nonlinearities in clearance and bioavailability.
|
Antimicrob Agents Chemother
|
2014
|
0.85
|
|
22
|
Single-dose pharmacokinetics of rifapentine in women.
|
J Pharmacokinet Biopharm
|
1998
|
0.82
|
|
23
|
Limited-sampling strategies for therapeutic drug monitoring of moxifloxacin in patients with tuberculosis.
|
Ther Drug Monit
|
2011
|
0.80
|